期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吲哚胺2,3-双加氧酶在肝癌组织的表达及其临床意义 被引量：2

Expression of indoleamine 2,3-dioxygenase in hepatocellular carcinoma and its clinical significance
下载PDF
导出
摘要 目的:探讨吲哚胺2,3-双加氧酶(indoleamine 2,3-dioxygenase,IDO)在原发性肝癌细胞、癌旁肝细胞及肿瘤浸润淋巴细胞中的表达及其临床意义。方法:选择经临床确诊的21例原发性肝癌患者的手术切除和(或)肝穿刺所取肝癌组织及癌旁组织标本,通过免疫组织化学染色法检测肝癌及癌旁组织IDO的表达,并分析其与临床病理特征的关系。结果:IDO在原发性肝癌细胞与肿瘤浸润淋巴细胞的表达水平相对较低,在癌旁肝硬变细胞中表达明显增高(P<0.01)。IDO表达强度与患者的年龄、性别、TNM分期无关(P>0.05);与患者大体病理分型有一定的相关性,浸润型IDO表达强度较块状型明显增高(P<0.05);有血管浸润及癌栓形成患者IDO也呈高表达状态(P<0.05);IDO的表达还与病理组织学分化情况相关,低分化肿瘤组织IDO的表达强度明显增高(P<0.05)。结论:IDO的表达与肝细胞癌恶性有一定的相关,故IDO拟可以作肝癌预后差的一个参考指标。
作者 武亚娟 王琦 武希润 董胜利 刘晓丽 张晓琴
机构地区 山西省肿瘤医院内科 山西医科大学第二医院消化内科 山西医科大学第二医院普外科 山西医科大学第二医院病理科
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2008年第6期585-587,共3页 Chinese Journal of Cancer Biotherapy
关键词 吲哚胺2 3-双加氧酶 肝癌 病理特征 预后
分类号 R735.7 [医药卫生—肿瘤] R730.2 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Terness P, Chuang JJ, Bauer T, et al. Regulation of human auto-and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO[J]? Blood, 2005, 105(6): 2480-2486.
  • 2Ishio T, Goto S, Tahara K, et al. Immunoaetivative role of indoleamine 2, 3-dioxygenase in human hepato-cellular carcinoma[J]. J Gastroenterol Hepatol, 2004, 19(3) : 319-326.
  • 3Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase[J]. Nat Med, 2003, 9(10) : 1269-1274.
  • 4唐晓琼,赵智刚,王红祥,李秋柏,吕建,邹萍华.急性髓细胞白血病细胞的吲哚胺2,3-双加氧酶介导免疫逃逸的实验研究[J].中国实验血液学杂志,2006,14(3):539-542. 被引量：7
  • 5Hou DY, Muller AJ, Sharma MD, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses[J].Cancer Res, 2007,67 (2) : 792-801.
  • 6Ino K, Yamamoto E, Shibata K,et al. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival[J]. Clin Cancer Res, 2008, 14 (8) :2310-2317.
  • 7Muller A J, Duhadaway JB, Donover PS, et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Binl, potentiates cancer chemother-apy[J]. Nat Med, 2005, 11(3): 312-319.
  • 8Pan K, Wang H, Chen MS, et al. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma [J]. J Cancer Res Clin Oncol, 2008, 134(11) : 1247-1253.
  • 9Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygemase by plasmacytoid dendritic cells in tumor-draining lymph nodes [ J ]. J Chin Invest, 2004,114 (2) : 280-290.
  • 10Astigiano S, Morandi B, Costa R, et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-midiated immune escape in human non-small cell lung cancer[J].Neoplasia, 2005, 7(4) : 390-396.

二级参考文献11

  • 1Gabrilovich D,Pisarev V.Tumor escapedfrom immune response:mechanisms and targets of activity.Curr Drug Targets,2003; 4:525-536
  • 2Melior AL,Munn DH.Tryptophan catabolism and T-cell tolerance:immunosuppression bystarvation? Immunol Today,1999; 20:469 -473
  • 3Terness P,Chuang J J,Bauer T,et al.Regulation of human autoand alloreactive T cells byindoleamine 2,3-dioxygenase (IDO)-producing dendritic cells:too much ado about IDO.?Blood,2005; 105:2480-2486
  • 4Logan GJ,Smyth CM,Earl JW,et al.HeLa cells cocultured with peripheral blood lymphocytesacquire an immuno-inhibitory phenotype through up-regulation of indoleamine2,3-dioxygenase activity.Immunology,2002; 105:478 -487
  • 5Thomas SM,Garrity LF,Brandt CR,et al.IFN-gamma-mediated antimicrobialresponse.Indoleamine 2,3-dioxygenase-deficient mutam host cells no longer inhibitintracellular Chlamydia spp.or Toxoplasma growth.J Immunol,1993; 150:5529-5534
  • 6Taylor MW,Feng GS.Relationship between interferon-gamma,indoleamine 2,3-dioxygenase,andtryptophan catabolism.FASEB J,1991; 5:2516 -2522
  • 7Mellor AL,Keskin DB,Johnson T,et al.Cells expressing indoleamine 2,3-dioxygenaseinhibit T cell responses.J Immunol,2002; 168:3771-3776
  • 8Munn DH,Shafizadeh E,Attwood JT,et al.Inhibition of T cell proliferation by macrophagetryptophan catabolism.J Exp Med,1999;189:1363-1372
  • 9Uyttenhove C,Pilotte L,Theate I,et al.Evidence for a tumoral immune resistancemechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.Nat Med,2003;9:1269-1274
  • 10Friberg M,Jennings R,Alsarraj M,et al.Indoleamine 2,3-dioxygenase contributes to tumorcell evasion of T cell-mediated rejection.Int J Cancer,2002; 101:151 -155

共引文献6

同被引文献23

  • 1Mellor AL,Munn DH.Tryptophan catabolism and T_cell tolerance:im-mune-suppression by strvationK?[J].Immunol Today,1999,20(10):469-473.
  • 2Puccetti P,Grohmann U.IDO and regulatory T cells:a role for reversesignaling and non-canonical NF-kappaB activation[J].Nat RevImmunol,2007,7(10):817-823.
  • 3Schroecksnadel K,Zangerle R,Bellmann-Weiler R,et al.Indoleam-ine-2,3-dioxygenase and other interferon-gamma-mediatedpathways in patients with human immunodeficiency virus infection[J].Curr Drug Metab,2007,8(3):225-236.
  • 4Brandacher G,Perathoner A,Ladurner R,et al.Prognostic value of in-doleamine 2,3-dioxygenase expression in colorectal cancer:effect ontumor-infiltrating T cells[J].Clin Cancer Res,2006,12(4):1144-1151.
  • 5Ino K,Yoshida N,Kajiyama H,et al.Indoleamine-2,3-dioxygenaseis a novel prognostic indicator for endometrial cancer[J].Br J Cancer,2006,95(11):1555-1561.
  • 6Nakamura T,Shima T,Saeki A,et al.Expression of indoleamine-2,3-dioxygenase and the recruitment of Foxp3-expressing regulatory Tcells in the development and progression of uterine cervical cancer[J].Cancer Sci,2007,98(6):874-881.
  • 7Nonaka H,Saga Y,Fujiwara H,et al.Indoleamine 2,3-dioxygenasepromotes peritoneal dissemination of ovarian cancer through inhibitionof natural killercell function and angiogenesis promotion[J].Int J On-col,2011,38(1):113-120.
  • 8Ishio T,Goto S,Tahara K,et al.Immunoactivative role of indoleamine2,3-dioxygenase in human hepatocellular carcinoma[J].J Gastroen-terol Hepatol,2004,19(3):319-326.
  • 9CHRISTIAN W, MATI?HIAS N. Cancer invasion and metastasi~ [J]. Oncology, 2005, 69(Suppl 1): 14.
  • 10GAJEWSKI TF, MENG Y, HARLIN H. Immune suppression in the tumor microenvironment[J]. J Immunother, 2006, 29(3): 233- 240.

引证文献2

二级引证文献3

中国肿瘤生物治疗杂志
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部